Please login to the form below

Not currently logged in
Email:
Password:

relugolix

This page shows the latest relugolix news and features for those working in and with pharma, biotech and healthcare.

AbbVie’s uterine fibroids drug aces second phase III trial

AbbVie’s uterine fibroids drug aces second phase III trial

Last year, Takeda and Myovant reported positive mid-stage results with their relugolix candidate in this indication as well as endometriosis-related pain and prostate cancer.

Latest news

  • Roivant gets $1.1bn investment from Japan's SoftBank Roivant gets $1.1bn investment from Japan's SoftBank

    Axovant for example is developing a GSK cast-off for Alzheimer's disease - serotonin 5-HT6 receptor antagonist RVT-101 - through late-stage testing, while Myovant is working on relugolix, a

  • Takeda forms new women's health and cancer company Takeda forms new women's health and cancer company

    For its tie-up with Takeda, the Japanese firm has granted Myovant Sciences an exclusive, worldwide license for its prostate cancer candidate relugolix, with the exception of Asian markets. ... Andrew Plump, chief medical and scientific officer at Takeda,

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics